Interleukin-1 receptor antagonist improves normoglycemia and insulin sensitivity in diabetic Goto-Kakizaki-rats

European Journal of Pharmacology

Volumn 701, Issue 1-3, 2013, Pages 87-95

  Akash, Muhammad Sajid Hamid ^a,b   Rehman, Kanwal ^a   Sun, Hongyin ^a   Chen, Shuqing ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

Author keywords

Diabetes mellitus; GK rat; Glucose tolerance test; Insulin resistance; Insulin tolerance test

Indexed keywords

GLUCOSE; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG HALF LIFE; DRUG TARGETING; EXPERIMENTAL RAT; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HOMEOSTASIS; HOMEOSTATIC MODEL ASSESSMENT; IMMUNOHISTOCHEMISTRY; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; MACROPHAGE MIGRATION; MALE; MATHEMATICAL MODEL; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX MODEL; QUANTITATIVE STUDY; RAT; WEIGHT GAIN;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; RATS; RECEPTORS, INTERLEUKIN-1;

EID: 84873693337     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.01.008     Document Type: Article

References (38)

1. M.S.H. Akash, K. Rehman, and S. Chen Role of inflammatory mechanism in pathogenesis of type 2 diabetes mellitus J. Cell. Biochem. 114 2013 525 531
2. M.S.H. Akash, K. Rehman, N. Li, J.Q. Gao, H. Sun, and S. Chen Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials Pharm. Res. 29 2012 3475 3485
3. M.S.H. Akash, K. Rehman, F. Rasool, A. Sethi, M.A. Abrar, A. Irshad, A. Abid, and G. Murtaza Alternate therapy of type 2 diabetes mellitus (T2DM) with Nigella (Ranunculaceae). J. Med. Plants Res. 5 2011 6885 6889
4. M.S.H. Akash, Q. Shen, K. Rehman, and S. Chen Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus J. Pharm. Sci. 101 2012 1647 1658
5. K. Argoud, S.P. Wilder, M.A. McAteer, M.T. Bihoreau, F. Ouali, P.Y. Woon, R.H. Wallis, A. Ktorza, and D. Gauguier Genetic control of plasma lipid levels in a cross derived from normoglycaemic Brown Norway and spontaneously diabetic Goto-Kakizaki rats Diabetologia 49 2006 2679 2688
6. M. Boni-Schnetzler, S. Boller, S. Debray, K. Bouzakri, D.T. Meier, R. Prazak, J. Kerr-Conte, F. Pattou, J.A. Ehses, F.C. Schuit, and M.Y. Donath Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I Endocrinology 150 2009 5218 5229
7. E.J. Boyko, and C.C. Jensen Do we know what homeostasis model assessment measures? If not, does it matter? Diabet. Care 30 2007 2729 2736
8. I. Briaud, C.L. Kelpe, L.M. Johnson, P.O. Tran, and V. Poitout Differential effects of hyperlipidemia on insulin secretion in islets of langerhans from hyperglycemic versus normoglycemic rats Diabetes 51 2002 662 668
9. P.A. Chyka, A.R. Erdman, G. Christianson, P.M. Wax, L.L. Booze, A.S. Manoguerra, E.M. Caravati, L.S. Nelson, K.R. Olson, D.J. Cobaugh, E.J. Scharman, A.D. Woolf, and W.G. Troutman Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management Clin. Toxicol. (Phila) 45 2007 95 131
10. J.M. Dayer, U. Feige, C.K. Edwards, and D. Burger Anti-interleukin-1 therapy in rheumatic diseases Curr. Opin. Rheumatol. 13 2001 170 176
11. C.A. Dinarello Biologic basis for interleukin-1 in disease Blood 87 1996 2095 2147
12. C.A. Dinarello The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1 N. Engl. J. Med. 343 2000 732 734
13. C.A. Dinarello Blocking interleukin-1β in acute and chronic autoinflammatory diseases J. Int. Med. 269 2011 16 28
14. M.Y. Donath, and S.E. Shoelson Type 2 diabetes as an inflammatory disease Nat. Rev. Immunol. 11 2011 98 107
15. M.Y. Donath, M. Boni-Schnetzler, H. Ellingsgaard, and J.A. Ehses Islet inflammation impairs the pancreatic β-cell in type 2 diabetes Physiology (Bethesda) 24 2009 325 331
16. M.Y. Donath, H. Ellingsgaard, D.M. Schumann, A. Perren, M. Faulenbach, and J.A. Ehses Islet inflammation in type 2 diabetes: from metabolic stress to therapy Diabet. Care 31 2008 S161 S164
17. J.A. Ehses, G. Lacraz, M. Giroix, F. Schmidlin, J. Coulaud, N. Kassis, J.C. Irminger, M. Kergoat, B. Portha, F. Homo-Delarche, and M.Y. Donath IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat Proc. Nat. Acad. Sci. U.S.A. 106 2009 13998 14003
18. J.A. Ehses, D.T. Meier, S. Wueest, J. Rytka, S. Boller, P.Y. Wielinga, A. Schraenen, K. Lemaire, S. Debray, L. Van Lommel, J.A. Pospisilik, O. Tschopp, S.M. Schultze, U. Malipiero, H. Esterbauer, H. Ellingsgaard, S. Rutti, F.C. Schuit, T.A. Lutz, M. Boni-Schnetzler, D. Konrad, and M.Y. Donath Toll-like receptor 2-deficient mice are protected from insulin resistance and β cell dysfunction induced by a high-fat diet Diabetologia 53 2010 1795 1806
19. J.A. Ehses, A. Perren, E. Eppler, P. Ribaux, J.A. Pospisilik, R. Maor-Cahn, X. Gueripel, H. Ellingsgaard, M.K. Schneider, G. Biollaz, A. Fontana, M. Reinecke, F. Homo-Delarche, and M.Y. Donath Increased number of islet associated macrophages in type 2 diabetes Diabetes 56 2007 2356 2370
20. H.Y. Gaisano, C.G. Ostenson, L. Sheu, M.B. Wheeler, and S. Efendic Abnormal expression of pancreatic islet exocytotic soluble N-ethylmaleimide- sensitive factor attachment protein receptors in Goto-Kakizaki rats is partially restored by phlorizin treatment and accentuated by high glucose treatment Endocrinology 143 2002 4218 4226
21. T. Gronholm, Z.J. Cheng, E. Palojoki, A. Eriksson, T. Backlund, O. Vuolteenaho, P. Finckenberg, M. Laine, E. Mervalla, and I. Tikkanen Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats Eur. J. Pharmacol. 519 2005 267 276
22. F. Homo-Delarche, S. Calderari, J.C. Irminger, M.N. Gangnerau, J. Coulaud, K. Rickenbach, M. Dolz, P. Halban, B. Portha, and P. Serradas Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat Diabetes 55 2006 1625 1633
23. A. Katz, S.S. Nambi, K. Mather, A.D. Baron, D.A. Follmann, G. Sullivan, and M.J. Quon Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans J. Clin. Endocrinol. Metab. 86 2000 2402 2410
24. G. Lacraz, M. Giroix, N. Kassis, J. Coulaud, A. Galinier, C. Noll, M. Cornut, F. Schmidlin, J.L. Paul, N. Janel, J.C. Irminger, M. Kergoat, B. Portha, M.Y. Donath, J.A. Ehses, and F. Homo-Delarche Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat PLoS One 4 2009 e6963
25. C.M. Larsen, M. Faulenbach, A. Vaag, A. Vølund, J.A. Ehses, B. Seifert, T. Mandrup- Poulsen, and M.Y. Donath Interleukin-1 receptor antagonist in type 2 diabetes mellitus N. Engl. J. Med. 356 2007 1517 1526
26. C.M. Larsen, M. Faulenbach, A. Vaag, J.A. Ehses, M.Y. Donath, and T. Mandrup-Poulsen Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes Diabet. Care 32 2009 1663 1668
27. G. Lavi, E. Voronov, C.A. Dinarello, R.N. Apte, and S. Cohen Sustained delivery of IL-1Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases J. Control Release 123 2007 123 130
28. K. Maedler, P. Sergeev, J.A. Ehses, Z. Mathe, D. Bosco, T. Berney, J.M. Dayer, M. Reinecke, P.A. Halban, and M.Y. Donath Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets Proc. Nat. Acad. Sci. U.S.A. 101 2004 8138 8143
29. K. Maedler, P. Sergeev, F. Ris, J. Oberholzer, H.I. Joller-Jemelka, G.A. Spinas, N. Kaiser, P.A. Halban, and M.Y. Donath Glucose-induced β-cell production of IL-1β contributes to glucotoxicity in human pancreatic islets J. Clin. Invest. 110 2002 851 860
30. T. Mandrup-Poulsen, L. Pickersgill, and M.Y. Donath Blockade of interleukin 1 in type 1 diabetes mellitus Nat. Rev. Endocrinol. 6 2010 158 166
31. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
32. J. Movassat, D. Bailbé, C. Lubrano-Berthelier, F. Picarel-Blanchot, E. Bertin, J. Mourot, and B. Portha Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion Am. J. Physiol. Endocrinol. Metab. 294 2008 E168 E175
33. B. Portha Programmed disorders of beta-cell development and function as one cause for type 2 diabetes? The GK rat paradigm Diabet. Metab. Res. Rev. 21 2005 495 504
34. S.J. Richardson, A. Willcox, A.J. Bone, A.K. Foulis, and N.G. Morgan Islet-associated macrophages in type 2 diabetes Diabetologia 52 2009 1686 1688
35. N.S. Sauter, F.T. Schulthess, R. Galasso, L.W. Castellani, and K. Maedler The anti-inflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia Endocrinology 149 2008 2208 2218
36. Y. Song, J.E. Manson, L. Tinker, B.V. Howard, L.H. Kuller, L. Nathan, N. Rifai, and S. Liu Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study Diabet. Care 30 2007 1747 1752
37. T.M. Wallace, J.C. Levy, and D.R. Matthews Use and abuse of HMOA modeling Diabet. Care 27 2004 1487 1495
38. R.H. Wallis, K.J. Wallace, S.C. Collins, M. Mc Ateer, K. Argoud, M.T. Bihoreau, P.J. Kaisaki, and D. Gauguier Enhanced insulin secretion and cholesterol metabolism in congenic strains of the spontaneously diabetic (type 2) Goto Kakizaki rat are controlled by independent genetic loci in rat chromosome 8 Diabetologia 47 2004 1096 1106